Pathways for salvage and protection of the heart under stress: Novel routes for cardiac rejuvenation

Cardiovascular Research

Volumn 111, Issue 2, 2016, Pages 142-153

  Cannatà, Antonio ^a,b   Camparini, Luca ^a   Sinagra, Gianfranco ^b   Giacca, Mauro ^a   Loffredo, Francesco S ^a,b  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Aging hormones; Caloric restriction; Cardiac aging; Cardiac hypertrophy; Cardiac rejuvenation

Indexed keywords

ANTIOXIDANT; CALCIUM; CONNECTIN; MICRORNA; TELOMERASE;

AGED; AGING; ANATOMICAL CONCEPTS; CALCIUM HOMEOSTASIS; CARDIAC MUSCLE; EXCITATION CONTRACTION COUPLING; EXTRACELLULAR MATRIX; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; HISTOLOGY; HUMAN; LIFE EXPECTANCY; MITOCHONDRION; OXIDATIVE STRESS; PRIORITY JOURNAL; REJUVENATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM CURRENT; TELOMERE; AGE; ANIMAL; ENERGY METABOLISM; HEALTH STATUS; HEART DISEASES; HEART MITOCHONDRION; LONGEVITY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; REGENERATION; RISK FACTOR;

AGE FACTORS; AGING; ANIMALS; ENERGY METABOLISM; HEALTH STATUS; HEART DISEASES; HUMANS; LONGEVITY; MITOCHONDRIA, HEART; MYOCARDIUM; REGENERATION; RISK FACTORS; STRESS, PHYSIOLOGICAL;

EID: 85007300574     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvw106     Document Type: Review

References (181)

1. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153:1194-1217.
2. Oh J, Lee YD, Wagers AJ. Stem cell aging: mechanisms, regulators and therapeutic opportunities. Nat Med 2014;20:870-880.
3. Hertel J, Friedrich N, Wittfeld K, Pietzner M, Budde K, Van der Auwera S, Lohmann T, Teumer A, Volzke H, Nauck M, Grabe HJ. Measuring biological age via metabonomics: The metabolic age score. J Proteome Res 2016;15:400-410.
4. De Luca d'Alessandro E, Bonacci S, Giraldi G. Aging populations: The health and quality of life of the elderly. Clin Ter 2011;162:e13-e18.
5. North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res 2012;110:1097-1108.
6. Larson MG. Assessment of cardiovascular risk factors in the elderly: The Framingham Heart Study. Stat Med 1995;14:1745-1756.
7. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, YehRW, Turner MB, American Heart Association Statistics C, Stroke Statistics S. Heart Disease and Stroke Statistics-2016 Update: A report from the American Heart Association. Circulation 2016;133:e38-e360.
8. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJ, Naghavi M. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: The Global Burden of Disease 2010 study. Circulation 2014;129:1483-1492.
9. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, Tian B, Wagner T, Vatner SF, Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007;100:1512-1521.
10. Desai A, Fang JC. Heart failure with preserved ejection fraction: hypertension, diabetes, obesity/sleep apnea, and hypertrophic and infiltrative cardiomyopathy. Heart Fail Clin 2008;4:87-97.
11. Ouzounian M, Lee DS, Liu PP. Diastolic heart failure: mechanisms and controversies. Nat Clin Pract Cardiovasc Med 2008;5:375-386.
12. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259.
13. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-269.
14. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005;47:320-332.
15. Paulus WJ. Novel strategies in diastolic heart failure. Heart 2010;96:1147-1153.
16. Servick K. Biomedicine. Woes for 'exercise hormone'. Science 2015;347:1299.
17. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age-And genderrelated ventricular-vascular stiffening: A community-based study. Circulation 2005; 112:2254-2262.
18. Dannenberg AL, Levy D, Garrison RJ. Impact of age on echocardiographic left ventricular mass in a healthy population (the Framingham Study). Am J Cardiol 1989;64: 1066-1068.
19. Chen CH, Nakayama M, Nevo E, Fetics BJ, Maughan WL, Kass DA. Coupled systolicventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol 1998;32:1221-1227.
20. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: The aging heart in health: links to heart disease. Circulation 2003;107:346-354.
21. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-458.
22. Kiatchoosakun S, Restivo J, Kirkpatrick D, Hoit BD. Assessment of left ventricular mass in mice: comparison between two-dimensional and m-mode echocardiography. Echocardiography 2002;19:199-205.
23. Vasan RS, Sullivan LM, D'Agostino RB, Roubenoff R, Harris T, Sawyer DB, Levy D, Wilson PW. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: The Framingham Heart Study. Ann Intern Med 2003;139:642-648.
24. Dai DF, Santana LF, Vermulst M, Tomazela DM, Emond MJ, MacCoss MJ, Gollahon K, Martin GM, Loeb LA, Ladiges WC, Rabinovitch PS. Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. Circulation 2009;119: 2789-2797.
25. Wang M, Zhang J, Walker SJ, Dworakowski R, Lakatta EG, Shah AM. Involvement of NADPH oxidase in age-Associated cardiac remodeling. J Mol Cell Cardiol 2010;48: 765-772.
26. Heinzel FR, Hohendanner F, Jin G, Sedej S, Edelmann F. Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. J Appl Physiol (1985) 2015;119: 1233-1242.
27. Treuting PM, Linford NJ, Knoblaugh SE, Emond MJ, Morton JF, Martin GM, Rabinovitch PS, Ladiges WC. Reduction of age-Associated pathology in old mice by overexpression of catalase in mitochondria. J Gerontol A Biol Sci Med Sci 2008;63: 813-822.
28. Yan L, Vatner DE, O'Connor JP, Ivessa A, Ge H, Chen W, Hirotani S, Ishikawa Y, Sadoshima J, Vatner SF. Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 2007;130:247-258.
29. Dai DF, Rabinovitch PS. Cardiac aging in mice and humans: The role of mitochondrial oxidative stress. Trends Cardiovasc Med 2009;19:213-220.
30. Kim Y, Nam HG, Valenzano DR. The short-lived African turquoise killifish: An emerging experimental model for ageing. Dis Model Mech 2016;9:115-129.
31. Barasch E, Gottdiener JS, Aurigemma G, Kitzman DW, Han J, Kop WJ, Tracy RP. The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: The Cardiovascular Health Study. Circ Heart Fail 2011;4:733-739.
32. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011;32:670-679.
33. Eghbali M, Eghbali M, Robinson TF, Seifter S, Blumenfeld OO. Collagen accumulation in heart ventricles as a function of growth and aging. Cardiovasc Res 1989;23:723-729.
34. Gazoti Debessa CR, Mesiano Maifrino LB, Rodrigues de Souza R. Age related changes of the collagen network of the human heart. Mech Ageing Dev 2001;122:1049-1058.
35. Kitzman DW. Diastolic heart failure in the elderly. Heart Fail Rev 2002;7:17-27.
36. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, Donnelly SC, McDonald K. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007;115:888-895.
37. Olivetti G, Giordano G, Corradi D, Melissari M, Lagrasta C, Gambert SR, Anversa P. Gender differences and aging: effects on the human heart. J Am Coll Cardiol 1995;26: 1068-1079.
38. Olivetti G, Melissari M, Balbi T, Quaini F, Sonnenblick EH, Anversa P. Myocyte nuclear and possible cellular hyperplasia contribute to ventricular remodeling in the hypertrophic senescent heart in humans. J Am Coll Cardiol 1994;24:140-149.
39. Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res 1991;68:1560-1568.
40. Swinne CJ, Shapiro EP, Jamart J, Fleg JL. Age-Associated changes in left ventricular outflow tract geometry in normal subjects. Am J Cardiol 1996;78:1070-1073.
41. Gottdiener JS, Bartz T, DeFilippi C, Kop W, Kitzman D, Barasch E, Seliger S, Lloyd-Jones D. Echocardiographic and biomarker phenotype of heart failure with preserved ejection fraction (HFPEF) in older individuals in comparison to hypertension without heart failure (HTN), elderly with risk factors, and healthy aging. Importance of myocyte injury, fibrosis, LV hypertrophy, and diastolic load. J Am Coll Cardiol 2012;59: E852-E852.
42. Groban L, Pailes NA, Bennett CD, Carter CS, Chappell MC, Kitzman DW, Sonntag WE. Growth hormone replacement attenuates diastolic dysfunction and cardiac angiotensin II expression in senescent rats. J Gerontol A Biol Sci Med Sci 2006; 61:28-35.
43. English BA, Appalsamy M, Diedrich A, Ruggiero AM, Lund D, Wright J, Keller NR, Louderback KM, Robertson D, Blakely RD. Tachycardia, reduced vagal capacity, and age-dependent ventricular dysfunction arising from diminished expression of the presynaptic choline transporter. Am J Physiol Heart Circ Physiol 2010;299: H799-H810.
44. Horvath S, Garagnani P, Bacalini MG, Pirazzini C, Salvioli S, Gentilini D, Di Blasio AM, Giuliani C, Tung S, Vinters HV, Franceschi C. Accelerated epigenetic aging in Down syndrome. Aging Cell 2015;14:491-495.
45. Ullrich NJ, Gordon LB. Hutchinson-Gilford progeria syndrome. Handb Clin Neurol 2015;132:249-264.
46. Uppal H, Chandran S, Potluri R. Risk factors for mortality in Down syndrome. J Intellect Disabil Res 2015;59:873-881.
47. Reichel W, Garcia-Bunuel R. Pathologic findings in progeria: myocardial fibrosis and lipofuscin pigment. Am J Clin Pathol 1970;53:243-253.
48. Ilyas S, Ilyas H, Hameed A, Ilyas M. Progeria syndrome with cardiac complications. J Pak Med Assoc 2013;63:1182-1185.
49. Bradshaw AD, Baicu CF, Rentz TJ, Van Laer AO, Bonnema DD, Zile MR. Agedependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Am J Physiol Heart Circ Physiol 2010;298:H614-H622.
50. Querejeta R, Lopez B, Gonzalez A, Sanchez E, Larman M, Martinez Ubago JL, Diez J. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 2004;110:1263-1268.
51. Guilbert M, Roig B, Terryn C, Garnotel R, Jeannesson P, Sockalingum GD, Manfait M, Perraut F, Dinten JM, Koenig A, Piot O. Highlighting the impact of aging on type I collagen: label-free investigation using confocal reflectance microscopy and diffuse reflectance spectroscopy in 3D matrix model. Oncotarget 2016;7:8546-8555.
52. Brooks WW, Conrad CH. Myocardial fibrosis in transforming growth factor beta(1)heterozygous mice. J Mol Cell Cardiol 2000;32:187-195.
53. Bonnema DD, Webb CS, Pennington WR, Stroud RE, Leonardi AE, Clark LL, McClure CD, Finklea L, Spinale FG, Zile MR. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail 2007;13:530-540.
54. Yabluchanskiy A, Ma Y, Chiao YA, Lopez EF, Voorhees AP, Toba H, Hall ME, Han HC, Lindsey ML, Jin YF. Cardiac aging is initiated by matrix metalloproteinase-9-mediated endothelial dysfunction. Am J Physiol Heart Circ Physiol 2014;306:H1398-H1407.
55. Meyer K, Hodwin B, Ramanujam D, Engelhardt S, Sarikas A. Essential role for premature senescence of myofibroblasts in myocardial fibrosis. J Am Coll Cardiol 2016;67: 2018-2028.
56. Kruger M, Kotter S, Grutzner A, Lang P, Andresen C, Redfield MM, Butt E, dos Remedios CG, Linke WA. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 2009;104:87-94.
57. Taylor M, Graw S, Sinagra G, Barnes C, Slavov D, Brun F, Pinamonti B, Salcedo EE, Sauer W, Pyxaras S, Anderson B, Simon B, Bogomolovas J, Labeit S, Granzier H, Mestroni L. Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy-overlap syndromes. Circulation 2011;124:876-885.
58. Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, Conner L, DePalma SR, McDonough B, Sparks E, Teodorescu DL, Cirino AL, Banner NR, Pennell DJ, Graw S, Merlo M, Di Lenarda A, Sinagra G, Bos JM, Ackerman MJ, Mitchell RN, Murry CE, Lakdawala NK, Ho CY, Barton PJ, Cook SA, Mestroni L, Seidman JG, Seidman CE. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012;366:619-628.
59. Hamdani N, Bishu KG, von Frieling-Salewsky M, Redfield MM, Linke WA. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovasc Res 2013;97:464-471.
60. Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ, Bradshaw AD, Slater R, Palmer BM, Van Buren P, Meyer M, Redfield MM, Bull DA, Granzier HL, LeWinter MM. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 2015;131:1247-1259.
61. Bishu K, Hamdani N, Mohammed SF, Kruger M, Ohtani T, Ogut O, Brozovich FV, Burnett JC Jr, Linke WA, Redfield MM. Sildenafil and B-Type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation 2011;124: 2882-2891.
62. Janczewski AM, Lakatta EG. Modulation of sarcoplasmic reticulum Ca(2+) cycling in systolic and diastolic heart failure associated with aging. Heart Fail Rev 2010;15: 431-445.
63. Babusikova E, Lehotsky J, Dobrota D, Racay P, Kaplan P. Age-Associated changes in Ca(2+)-ATPase and oxidative damage in sarcoplasmic reticulum of rat heart. Physiol Res 2012;61:453-460.
64. Howlett SE, Grandy SA, Ferrier GR. Calcium spark properties in ventricular myocytes are altered in aged mice. Am J Physiol Heart Circ Physiol 2006;290:H1566-H1574.
65. Bers DM. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 2008;70: 23-49.
66. Kaplan P, Jurkovicova D, Babusikova E, Hudecova S, Racay P, Sirova M, Lehotsky J, Drgova A, Dobrota D, Krizanova O. Effect of aging on the expression of intracellular Ca(2+) transport proteins in a rat heart. Mol Cell Biochem 2007;301:219-226.
67. Signore S, Sorrentino A, Ferreira-Martins J, Kannappan R, Shafaie M, Del Ben F, Isobe K, Arranto C, Wybieralska E, Webster A, Sanada F, Ogorek B, Zheng H, Liu X, Del Monte F, D'Alessandro DA, Wunimenghe O, Michler RE, Hosoda T, Goichberg P, Leri A, Kajstura J, Anversa P, Rota M. Inositol 1, 4, 5-Trisphosphate receptors and human left ventricular myocytes. Circulation 2013;128:1286-1297.
68. Eder P, Molkentin JD. TRPC channels as effectors of cardiac hypertrophy. Circ Res 2011;108:265-272.
69. del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW, Gwathmey JK, Rosenzweig A, Hajjar RJ. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 1999;100: 2308-2311.
70. Schmidt U, del Monte F, Miyamoto MI, Matsui T, Gwathmey JK, Rosenzweig A, Hajjar RJ. Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. Circulation 2000;101: 790-796.
71. Li Q, Wu S, Li SY, Lopez FL, Du M, Kajstura J, Anversa P, Ren J. Cardiac-specific overexpression of insulin-like growth factor 1 attenuates aging-Associated cardiac diastolic contractile dysfunction and protein damage. Am J Physiol Heart Circ Physiol 2007;292: H1398-H1403.
72. Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, Hajjar RJ. Longterm effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: Analysis of recurrent cardiovascular events and mortality. Circ Res 2014;114:101-108.
73. Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, Barnard D, Bouchard A, Jaski B, Lyon AR, Pogoda JM, Rudy JJ, Zsebo KM. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): A randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet 2016;387:1178-1186.
74. Aguero J, Ishikawa K, Hadri L, Santos-Gallego CG, Fish KM, Kohlbrenner E, Hammoudi N, Kho C, Lee A, Ibanez B, Garcia-Alvarez A, Zsebo K, Maron BA, Plataki M, Fuster V, Leopold JA, Hajjar RJ. Intratracheal gene delivery of SERCA2a ameliorates chronic post-capillary pulmonary hypertension: A large animal model. J Am Coll Cardiol 2016;67:2032-2046.
75. Ayaz O, Howlett SE. Testosterone modulates cardiac contraction and calcium homeostasis: cellular and molecular mechanisms. Biol Sex Differ 2015;6:9.
76. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS. Effects of Testosterone Treatment in Older Men. N Engl J Med 2016;374:611-624.
77. Abd Alamir M, Ellenberg SS, Swerdloff RS, Wenger NK, Mohler ER 3rd, Lewis CE, Barrett-Conner E, Nakanishi R, Darabian S, Alani A, Matsumoto S, Nezarat N, Snyder PJ, Budoff MJ. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coron Artery Dis 2016;27:95-103.
78. Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin 2009;27:13-24, vii.
79. Herraiz-Martinez A, Alvarez-Garcia J, Llach A, Molina CE, Fernandes J, Ferrero- Gregori A, Rodriguez C, Vallmitjana A, Benitez R, Padro JM, Martinez-Gonzalez J, Cinca J, Hove-Madsen L. Ageing is associated with deterioration of calcium homeostasis in isolated human right atrial myocytes. Cardiovasc Res 2015;106:76-86.
80. Xu GJ, Gan TY, Tang BP, Chen ZH, Jiang T, Song JG, Guo X, Li JX. Age-related changes in cellular electrophysiology and calcium handling for atrial fibrillation. J Cell Mol Med 2013;17:1109-1118.
81. Sah R, Ramirez RJ, Kaprielian R, Backx PH. Alterations in action potential profile enhance excitation-contraction coupling in rat cardiac myocytes. J Physiol 2001;533: 201-214.
82. Signore S, Sorrentino A, Borghetti G, Cannata A, Meo M, Zhou Y, Kannappan R, Pasqualini F, O'Malley H, Sundman M, Tsigkas N, Zhang E, Arranto C, Mangiaracina C, Isobe K, Sena BF, Kim J, Goichberg P, Nahrendorf M, Isom LL, Leri A, Anversa P, Rota M. Late Na(+) current and protracted electrical recovery are critical determinants of the aging myopathy. Nat Commun 2015;6:8803.
83. Sorrentino A, Signore S, Qanud K, Borghetti G, Meo M, Cannata A, Zhou Y, Wybieralska E, Luciani M, Kannappan R, Zhang E, Matsuda A, Webster A, Cimini M, Kertowidjojo E, D'Alessandro DA, Wunimenghe O, Michler RE, Royer CM, Goichberg P, Leri A, Barrett EG, Anversa P, Hintze TH, Rota M. Myocyte repolarization modulates myocardial function in aging dogs. Am J Physiol Heart Circ Physiol 2016;310:H873-H890.
84. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, WangW, Nelson JJ, Hebert DA, Wolff AA, Investigators M. Anti-ischemic effects and long-Term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-1382.
85. Williams S, Pourrier M, McAfee D, Lin S, Fedida D. Ranolazine improves diastolic function in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2014;306: H867-H881.
86. Aistrup GL, Gupta DK, Kelly JE, O'Toole MJ, Nahhas A, Chirayil N, Misener S, Beussink L, Singh N, Ng J, Reddy M, Mongkolrattanothai T, El-Bizri N, Rajamani S, Shryock JC, Belardinelli L, Shah SJ, Wasserstrom JA. Inhibition of the late sodium current slows t-Tubule disruption during the progression of hypertensive heart disease in the rat. Am J Physiol Heart Circ Physiol 2013;305:H1068-H1079.
87. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Guidelines ESCCfP. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33:1787-1847.
88. Basso N, Cini R, Pietrelli A, Ferder L, Terragno NA, Inserra F. Protective effect of longterm angiotensin II inhibition. Am J Physiol Heart Circ Physiol 2007;293:H1351-H1358.
89. Schnee JM, Hsueh WA. Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc Res 2000;46:264-268.
90. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM, Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 2009;119:524-530.
91. Ma LJ, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, Fogo AB. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 2000;58:2425-2436.
92. Donato AJ, Gano LB, Eskurza I, Silver AE, Gates PE, Jablonski K, Seals DR. Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol 2009;297:H425-H432.
93. Thijssen DH, Rongen GA, van Dijk A, Smits P, Hopman MT. Enhanced endothelin-1- mediated leg vascular tone in healthy older subjects. J Appl Physiol (1985) 2007;103: 852-857.
94. Wang X, Guo Z, Ding Z, Khaidakov M, Lin J, Xu Z, Sharma SG, Jiwani S, Mehta JL. Endothelin-1 upregulation mediates aging-related cardiac fibrosis. J Mol Cell Cardiol 2015;80:101-109.
95. Hathaway CK, Grant R, Hagaman JR, Hiller S, Li F, Xu L, Chang AS, Madden VJ, Bagnell CR, Rojas M, Kim HS, Wu B, Zhou B, Smithies O, Kakoki M. Endothelin-1 critically influences cardiac function via superoxide-MMP9 cascade. Proc Natl Acad Sci USA 2015;112:5141-5146.
96. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuroo M. Suppression of aging in mice by the hormone Klotho. Science 2005;309:1829-1833.
97. Wang Y, Sun Z. Antiaging gene Klotho regulates endothelin-1 levels and endothelin receptor subtype B expression in kidneys of spontaneously hypertensive rats. J Hypertens 2014;32:1629-1636; discussion 1636.
98. Westermeier F, Bustamante M, Pavez M, Garcia L, Chiong M, Ocaranza MP, Lavandero S. Novel players in cardioprotection: Insulin like growth factor-1, angiotensin-(1-7) and angiotensin-(1-9). Pharmacol Res 2015;101:41-55.
99. Vuille-dit-Bille RN, Camargo SM, Emmenegger L, Sasse T, Kummer E, Jando J, Hamie QM, Meier CF, Hunziker S, Forras-Kaufmann Z, Kuyumcu S, Fox M, Schwizer W, Fried M, Lindenmeyer M, Gotze O, Verrey F. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids 2015;47:693-705.
100. Jiang F, Yang J, Zhang Y, Dong M, Wang S, Zhang Q, Liu FF, Zhang K, Zhang C. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol 2014;11:413-426.
101. Lin L, Liu X, Xu J, Weng L, Ren J, Ge J, Zou Y. Mas receptor mediates cardioprotection of angiotensin-(1-7) against Angiotensin II-induced cardiomyocyte autophagy and cardiac remodelling through inhibition of oxidative stress. J Cell Mol Med 2016;20: 48-57.
102. Flores-Munoz M, Work LM, Douglas K, Denby L, Dominiczak AF, Graham D, Nicklin SA. Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. Hypertension 2012;59: 300-307.
103. Ocaranza MP, Lavandero S, Jalil JE, Moya J, Pinto M, Novoa U, Apablaza F, Gonzalez L, Hernandez C, Varas M, Lopez R, Godoy I, Verdejo H, Chiong M. Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens 2010;28:1054-1064.
104. Lelli D, Pedone C, Rossi FF, Incalzi RA. Clinical and echocardiographic characteristics of elderly hospitalized patients with high levels of NT-proBNP without clinical diagnosis of heart failure. Aging Clin Exp Res 2014;26:607-613.
105. Thomas CJ, McAllen RM, Salo LM, Woods RL. Restorative effect of atrial natriuretic peptide or chronic neutral endopeptidase inhibition on blunted cardiopulmonary vagal reflexes in aged rats. Hypertension 2008;52:696-701.
106. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators P-H, Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993-1004.
107. von Lueder TG, Wang BH, Kompa AR, Huang L, Webb R, Jordaan P, Atar D, Krum H. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail 2015;8:71-78.
108. Jhund PS, Claggett BL, Voors AA, Zile MR, Packer M, Pieske BM, Kraigher-Krainer E, Shah AM, Prescott MF, Shi V, Lefkowitz M, McMurray JJ, Solomon SD, Investigators P. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ Heart Fail 2014;7:953-959.
109. Bai HY, Mogi M, Nakaoka H, Kan-No H, Tsukuda K, Chisaka T, Wang XL, Kukida M, Shan BS, Yamauchi T, Higaki A, Iwanami J, Horiuchi M. Pre-Treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage. Eur J Pharmacol 2015;762:293-298.
110. Wang BH, von Lueder TG, Kompa AR, Huang L, Webb R, Jordaan P, Atar D, Krum H. Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis. Int J Cardiol 2015;186: 104-105.
111. Voors AA, Gori M, Liu LC, Claggett B, Zile MR, Pieske B, McMurray JJ, Packer M, Shi V, Lefkowitz MP, Solomon SD, Investigators P. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2015;17:510-517.
112. Fearon IM, Faux SP. Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J Mol Cell Cardiol 2009;47:372-381.
113. Terzioglu M, Larsson NG. Mitochondrial dysfunction in mammalian ageing. Novartis Found Symp 2007;287:197-208; discussion 208-113.
114. Dai DF, Chen T, Wanagat J, Laflamme M, Marcinek DJ, Emond MJ, Ngo CP, Prolla TA, Rabinovitch PS. Age-dependent cardiomyopathy in mitochondrial mutator mice is attenuated by overexpression of catalase targeted to mitochondria. Aging Cell 2010;9: 536-544.
115. Wang K, Klionsky DJ. Mitochondria removal by autophagy. Autophagy 2011;7: 297-300.
116. Lee J, Giordano S, Zhang J. Autophagy, mitochondria and oxidative stress: cross-Talk and redox signalling. Biochem J 2012;441:523-540.
117. Russell RC, Yuan HX, Guan KL. Autophagy regulation by nutrient signaling. Cell Res 2014;24:42-57.
118. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005;97:900-907.
119. Dai DF, Johnson SC, Villarin JJ, Chin MT, Nieves-Cintron M, Chen T, Marcinek DJ, Dorn GW 2nd, Kang YJ, Prolla TA, Santana LF, Rabinovitch PS. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res 2011;108:837-846.
120. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004;23:2369-2380.
121. Salminen A, Kaarniranta K. AMP-Activated protein kinase (AMPK) controls the aging process via an integrated signaling network. Ageing Res Rev 2012;11:230-241.
122. Hardie DG. AMPK: A target for drugs and natural products with effects on both diabetes and cancer. Diabetes 2013;62:2164-2172.
123. Chiao YA, Kolwicz SC, Basisty N, Gagnidze A, Zhang J, Gu H, Djukovic D, Beyer RP, Raftery D, MacCoss M, Tian R, Rabinovitch PS. Rapamycin transiently induces mitochondrial remodeling to reprogram energy metabolism in old hearts. Aging (Albany NY) 2016;8:314-327.
124. Szeto HH, James LP, Atkinson AJ. Mitochondrial pharmacology: its future is now. Clin Pharmacol Ther 2014;96:629-633.
125. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 2007;47:629-656.
126. Antoniades C, Bakogiannis C, Tousoulis D, Reilly S, Zhang MH, Paschalis A, Antonopoulos AS, Demosthenous M, Miliou A, Psarros C, Marinou K, Sfyras N, Economopoulos G, Casadei B, Channon KM, Stefanadis C. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation 2010;122:S66-S73.
127. Olivieri F, Mazzanti I, Abbatecola AM, Recchioni R, Marcheselli F, Procopio AD, Antonicelli R. Telomere/telomerase system: A new target of statins pleiotropic effect? Curr Vasc Pharmacol 2012;10:216-224.
128. Barlaka E, Galatou E, Mellidis K, Ravingerova T, Lazou A. Role of pleiotropic properties of peroxisome proliferator-Activated receptors in the heart: focus on the nonmetabolic effects in cardiac protection. Cardiovasc Ther 2016;34:37-48.
129. Szeto HH, Birk AV. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clin Pharmacol Ther 2014;96:672-683.
130. Birk AV, Liu S, Soong Y, MillsW, Singh P, Warren JD, Seshan SV, Pardee JD, Szeto HH. The mitochondrial-Targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol 2013;24:1250-1261.
131. Moslehi J, DePinho RA, Sahin E. Telomeres and mitochondria in the aging heart. Circ Res 2012;110:1226-1237.
132. Mitchell C, Hobcraft J, McLanahan SS, Siegel SR, Berg A, Brooks-Gunn J, Garfinkel I, Notterman D. Social disadvantage, genetic sensitivity, and children's telomere length. Proc Natl Acad Sci USA 2014;111:5944-5949.
133. Geronimus AT, Hicken MT, Pearson JA, Seashols SJ, Brown KL, Cruz TD. Do US black women experience stress-related accelerated biological aging?: A novel theory and first population-based test of black-white differences in telomere length. Hum Nat 2010;21:19-38.
134. Huzen J, de Boer RA, van Veldhuisen DJ, van Gilst WH, van der Harst P. The emerging role of telomere biology in cardiovascular disease. Front Biosci (Landmark Ed) 2010;15: 35-45.
135. Loprinzi PD. Cardiorespiratory capacity and leukocyte telomere length among adults in the United States. Am J Epidemiol 2015;182:198-201.
136. Denham J, O'Brien BJ, Prestes PR, Brown NJ, Charchar FJ. Increased expression of telomere-regulating genes in endurance athletes with long leukocyte telomeres. J Appl Physiol (1985) 2016;120:148-158.
137. Kirwan M, Dokal I. Dyskeratosis congenita, stem cells and telomeres. Biochim Biophys Acta 2009;1792:371-379.
138. Wong LS, Oeseburg H, de Boer RA, van Gilst WH, van Veldhuisen DJ, van der Harst P. Telomere biology in cardiovascular disease: The TERC-/- mouse as a model for heart failure and ageing. Cardiovasc Res 2009;81:244-252.
139. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA, Greider CW. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997;91:25-34.
140. Ludlow AT, Roth SM. Physical activity and telomere biology: exploring the link with aging-related disease prevention. J Aging Res 2011;2011:790378.
141. Sahin E, Colla S, Liesa M, Moslehi J, Muller FL, Guo M, Cooper M, Kotton D, Fabian AJ, Walkey C, Maser RS, Tonon G, Foerster F, Xiong R, Wang YA, Shukla SA, Jaskelioff M, Martin ES, Heffernan TP, Protopopov A, Ivanova E, Mahoney JE, Kost-Alimova M, Perry SR, Bronson R, Liao R, Mulligan R, Shirihai OS, Chin L, DePinho RA. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011;470: 359-365.
142. Sahin E, Depinho RA. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 2010;464:520-528.
143. Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, Greider CW, DePinho RA. p53 Deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999;97:527-538.
144. Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, Smith LK, Bieri G, Lin K, Berdnik D, Wabl R, Udeochu J, Wheatley EG, Zou B, Simmons DA, Xie XS, Longo FM, Wyss-Coray T. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med 2014;20:659-663.
145. Katsimpardi L, Litterman NK, Schein PA, Miller CM, Loffredo FS, Wojtkiewicz GR, Chen JW, Lee RT, Wagers AJ, Rubin LL. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 2014;344:630-634.
146. Loffredo FS, Steinhauser ML, Jay SM, Gannon J, Pancoast JR, Yalamanchi P, Sinha M, Dall'osso C, Khong D, Shadrach JL, Miller CM, Singer BS, Stewart A, Psychogios N, Gerszten RE, Hartigan AJ, Kim MJ, Serwold T, Wagers AJ, Lee RT. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 2013;153:828-839.
147. Egerman MA, Cadena SM, Gilbert JA, Meyer A, Nelson HN, Swalley SE, Mallozzi C, Jacobi C, Jennings LL, Clay I, Laurent G, Ma S, Brachat S, Lach-Trifilieff E, Shavlakadze T, Trendelenburg AU, Brack AS, Glass DJ. GDF11 increases with age and inhibits skeletal muscle regeneration. Cell Metabol 2015;22:164-174.
148. Smith SC, Zhang X, Zhang X, Gross P, Starosta T, Mohsin S, Franti M, Gupta P, Hayes D, Myzithras M, Kahn J, Tanner J, Weldon SM, Khalil A, Guo X, Sabri A, Chen X, MacDonnell S, Houser SR. GDF11 does not rescue aging-related pathological hypertrophy. Circ Res 2015;117:926-932.
149. Poggioli T, Vujic A, Yang P, Macias-Trevino C, Uygur A, Loffredo S, Pancoast JR, Cho M, Goldstein J, Tandias RM, Walker RG, Thompson TB, Wagers AJ, Fong YW, Richard T, Lee RT. Circulating growth differentiation factor 11/8 levels decline with age. Circ Res 2016;118:29-37.
150. McNally EM. Questions and answers about myostatin, GDF11, and the aging heart. Circ Res 2016;118:6-8.
151. Olson KA, Beatty AL, Heidecker B, Regan MC, Brody EN, Foreman T, Kato S, Mehler RE, Singer BS, Hveem K, Dalen H, Sterling DG, Lawn RM, Schiller NB, Williams SA, Whooley MA, Ganz P. Association of growth differentiation factor 11/8, putative anti-Ageing factor, with cardiovascular outcomes and overall mortality in humans: Analysis of the Heart and Soul and HUNT3 cohorts. Eur Heart J 2015;36: 3426-3434.
152. Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S, Giacca M. Functional screening identifies miRNAs inducing cardiac regeneration. Nature 2012;492: 376-381.
153. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007;100:416-424.
154. Kumarswamy R, Thum T. Non-coding RNAs in cardiac remodeling and heart failure. Circ Res 2013;113:676-689.
155. Smith-Vikos T, Slack FJ. MicroRNAs and their roles in aging. J Cell Sci 2012;125:7-17.
156. Jung HJ, Suh Y. Micro RNA in aging: from discovery to biology. Curr Genomics 2012;13: 548-557.
157. Noren Hooten N, Fitzpatrick M, Wood WH 3rd, De S, Ejiogu N, Zhang Y, Mattison JA, Becker KG, Zonderman AB, Evans MK. Age-related changes in micro- RNA levels in serum. Aging (Albany NY) 2013;5:725-740.
158. Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S, Kaluza D, Treguer K, Carmona G, Bonauer A, Horrevoets AJ, Didier N, Girmatsion Z, Biliczki P, Ehrlich JR, Katus HA, Muller OJ, Potente M, Zeiher AM, Hermeking H, Dimmeler S. MicroRNA-34a regulates cardiac ageing and function. Nature 2013;495:107-110.
159. Loffredo FS, Pancoast JR, Lee RT. Keep PNUTS in your heart. Circ Res 2013;113: 97-99.
160. Jazbutyte V, Fiedler J, Kneitz S, Galuppo P, Just A, Holzmann A, Bauersachs J, Thum T. MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age (Dordr) 2013;35:747-762.
161. van Almen GC, Verhesen W, van Leeuwen RE, van de Vrie M, Eurlings C, Schellings MW, Swinnen M, Cleutjens JP, van Zandvoort MA, Heymans S, Schroen B. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell 2011;10:769-779.
162. Jakob P, Doerries C, Briand S, Mocharla P, Krankel N, Besler C, Mueller M, Manes C, Templin C, Baltes C, Rudin M, Adams H, Wolfrum M, Noll G, Ruschitzka F, Luscher TF, Landmesser U. Loss of angiomiR-126 and 130a in angiogenic early outgrowth cells from patients with chronic heart failure: role for impaired in vivo neovascularization and cardiac repair capacity. Circulation 2012;126:2962-2975.
163. Zhu S, Deng S, Ma Q, Zhang T, Jia C, Zhuo D, Yang F, Wei J, Wang L, Dykxhoorn DM, Hare JM, Goldschmidt-Clermont PJ, Dong C. MicroRNA-10A∗ and MicroRNA-21 modulate endothelial progenitor cell senescence via suppressing high-mobility group A2. Circ Res 2013;112:152-164.
164. Bonawitz ND, Shadel GS. Rethinking the mitochondrial theory of aging: The role of mitochondrial gene expression in lifespan determination. Cell Cycle 2007;6: 1574-1578.
165. Wenz T, Wang X, Marini M, Moraes CT. A metabolic shift induced by a PPAR panagonist markedly reduces the effects of pathogenic mitochondrial tRNA mutations. J Cell Mol Med 2011;15:2317-2325.
166. Fontana L, Partridge L, Longo VD. Extending healthy life span-from yeast to humans. Science 2010;328:321-326.
167. Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab 2014;19:181-192.
168. Niemann B, Chen Y, Issa H, Silber RE, Rohrbach S. Caloric restriction delays cardiac ageing in rats: role of mitochondria. Cardiovasc Res 2010;88:267-276.
169. Rodgers JT, Lerin C, Gerhart-Hines Z, Puigserver P. Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett 2008;582:46-53.
170. Guarente L. Calorie restriction and sirtuins revisited. Genes Dev 2013;27:2072-2085.
171. Hubbard BP, Sinclair DA. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci 2014;35:146-154.
172. Libri V, Brown AP, Gambarota G, Haddad J, Shields GS, Dawes H, Pinato DJ, Hoffman E, Elliot PJ, Vlasuk GP, Jacobson E, Wilkins MR, Matthews PM. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PloS One 2012;7:e51395.
173. Pillai VB, Sundaresan NR, Gupta MP. Regulation of Akt signaling by sirtuins: its implication in cardiac hypertrophy and aging. Circ Res 2014;114:368-378.
174. Oka S, Alcendor R, Zhai P, Park JY, Shao D, Cho J, Yamamoto T, Tian B, Sadoshima J. PPARalpha-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway. Cell Metab 2011;14:598-611.
175. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006;127:1109-1122.
176. Tung BT, Rodriguez-Bies E, Thanh HN, Le-Thi-Thu H, Navas P, Sanchez VM, Lopez-Lluch G. Organ and tissue-dependent effect of resveratrol and exercise on antioxidant defenses of old mice. Aging Clin Exp Res 2015;27:775-783.
177. Zhang Y, Mi SL, Hu N, Doser TA, Sun A, Ge J, Ren J. Mitochondrial aldehyde dehydrogenase 2 accentuates aging-induced cardiac remodeling and contractile dysfunction: role of AMPK, Sirt1, and mitochondrial function. Free Radic Biol Med 2014;71: 208-220.
178. Sin TK, Yu AP, Yung BY, Yip SP, Chan LW, Wong CS, Ying M, Rudd JA, Siu PM. Modulating effect of SIRT1 activation induced by resveratrol on Foxo1-Associated apoptotic signalling in senescent heart. J Physiol 2014;592:2535-2548.
179. Tome-Carneiro J, Gonzalvez M, Larrosa M, Yanez-Gascon MJ, Garcia-Almagro FJ, Ruiz-Ros JA, Tomas-Barberan FA, Garcia-Conesa MT, Espin JC. Resveratrol in primary and secondary prevention of cardiovascular disease: A dietary and clinical perspective. Ann N Y Acad Sci 2013;1290:37-51.
180. Safdar A, Bourgeois JM, Ogborn DI, Little JP, Hettinga BP, Akhtar M, Thompson JE, Melov S, Mocellin NJ, Kujoth GC, Prolla TA, Tarnopolsky MA. Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice. Proc Natl Acad Sci USA 2011;108:4135-4140.
181. Lanza IR, Short DK, Short KR, Raghavakaimal S, Basu R, Joyner MJ, McConnell JP, Nair KS. Endurance exercise as a countermeasure for aging. Diabetes 2008;57:2933-2942.